ID   VA-ES-BJ
AC   CVCL_1785
SY   VAESBJ; Valhalla-Epithelioid Sarcoma-BJ
DR   CLO; CLO_0009509
DR   CLDB; cl4635
DR   CLDB; cl4636
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2138
DR   BioSample; SAMN03472555
DR   Cell_Model_Passport; SIDM01179
DR   ChEMBL-Cells; CHEMBL3308888
DR   ChEMBL-Targets; CHEMBL2366259
DR   Cosmic; 688121
DR   Cosmic-CLP; 688121
DR   DepMap; ACH-001702
DR   DSMZ; ACC-328
DR   DSMZCellDive; ACC-328
DR   ECACC; 94092303
DR   EGA; EGAS00001000978
DR   GDSC; 688121
DR   GEO; GSM1632462
DR   GEO; GSM1632463
DR   GEO; GSM1632464
DR   GEO; GSM1632465
DR   GEO; GSM1670569
DR   GEO; GSM1676344
DR   GEO; GSM1701675
DR   GEO; GSM2409694
DR   GEO; GSM2409695
DR   GEO; GSM2409696
DR   GEO; GSM2409697
DR   GEO; GSM2409698
DR   GEO; GSM2409699
DR   GEO; GSM2787358
DR   IARC_TP53; 21268
DR   ICLC; HTL97024
DR   LINCS_LDP; LCL-1945
DR   PharmacoDB; VAESBJ_1651_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1785
DR   Wikidata; Q54992642
RX   PubMed=11668190;
RX   PubMed=20164919;
RX   PubMed=21357725;
RX   PubMed=21552805;
RX   PubMed=26351324;
RX   PubMed=26365879;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28945250;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 36-39 hours (PubMed=21552805); ~32 hours (PubMed=21357725); ~60-90 hours (DSMZ=ACC-328).
CC   Karyotypic information: Near triploid karyotype. Trisomy of chromosomes 2, 5, 8, 10, 12, 13, 16, 17, 18 and 19, tetrasomy of chromosomes 6, 20 and 21 and pentasomy of chromosome 7 (PubMed=21552805).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.49%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=3.35%; European, North=67.75%; European, South=28.41% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; Cosmic-CLP; DepMap; DSMZ; ECACC; ICLC
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 12,13
ST   D19S433: 14
ST   D21S11: 27,28
ST   D2S1338: 16
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 11,12
ST   D8S1179: 11 (DSMZ)
ST   D8S1179: 11,15 (DepMap)
ST   FGA: 22
ST   Penta D: 7,10,13 (DepMap)
ST   Penta D: 10,13 (DSMZ)
ST   Penta E: 13
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C3714; Epithelioid sarcoma
DI   ORDO; Orphanet_293202; Epithelioid sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 35
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21357725; DOI=10.1634/theoncologist.2010-0174;
RA   Sakharpe A., Lahat G., Gulamhusein T., Liu P., Bolshakov S.V.,
RA   Nguyen T., Zhang P.-Y., Belousov R., Young E.D., Xie X.-B., Rao P.,
RA   Hornick J.L., Lazar A.J.F., Pollock R.E., Lev D.C.;
RT   "Epithelioid sarcoma and unclassified sarcoma with epithelioid
RT   features: clinicopathological variables, molecular markers, and a new
RT   experimental model.";
RL   Oncologist 16:512-522(2011).
//
RX   PubMed=21552805; DOI=10.3892/ijo.7.1.51;
RA   Helson C., Melamed M.R., Braverman S., Traganos F., Preti R.A.,
RA   Helson L.;
RT   "VA-ES-BJ -- an epithelioid sarcoma cell-line.";
RL   Int. J. Oncol. 7:51-56(1995).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26365879; DOI=10.1002/path.4636;
RA   Jamshidi F., Bashashati A., Shumansky K., Dickson B., Gokgoz N.,
RA   Wunder J.S., Andrulis I.L., Lazar A.J.F., Shah S.P., Huntsman D.G.,
RA   Nielsen T.O.;
RT   "The genomic landscape of epithelioid sarcoma cell lines and
RT   tumours.";
RL   J. Pathol. 238:63-73(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28945250; DOI=10.1038/ng.3958;
RA   Nakayama R.T., Pulice J.L., Valencia A.M., McBride M.J.,
RA   McKenzie Z.M., Gillespie M.A., Ku W.L., Teng M.-X., Cui K.-R.,
RA   Williams R.T., Cassel S.H., Qing H., Widmer C.J., Demetri G.D.,
RA   Irizarry R.A., Zhao K.-J., Ranish J.A., Kadoch C.;
RT   "SMARCB1 is required for widespread BAF complex-mediated activation of
RT   enhancers and bivalent promoters.";
RL   Nat. Genet. 49:1613-1623(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//